Immuron Limited shares rose more than 60% Friday after the Australian biopharmaceutical company announced an exclusive agreement with Sweden’s Calmino Group AB to bring Proibs to the United States. The stock reached levels last seen in November 2025 and was on pace for its strongest single-day gain since March 2024, with more than 80 million shares traded versus an average of roughly 16,000. Retail sentiment on Stocktwits turned extremely bullish. Proibs is a European-certified medical device for abdominal pain, bloating, diarrhea and constipation. Its active ingredient, AVH200, is derived from Aloe barbadensis Mill. and contains gel-forming components that support the intestinal mucosal barrier. In a Calmino usability study of 1,003 participants, 94% found the product helpful, 91% reported improvements in daily life and 98% said they would recommend it. Immuron is targeting the $4.16 billion U.S. digestive and gut-health supplement market after Proibs launched in Australia during fiscal year 2026. The company is expanding beyond Travelan, its primary commercial product, while advancing IMM-529, an experimental oral treatment for recurrent Clostridioides difficile infection. The U.S. Food and Drug Administration approved Immuron’s Investigational New Drug application last November, clearing the way for a Phase 2 trial. Lumanity estimates IMM-529 could reach peak U.S. sales of $400 million. Immuron shares have gained about 135% this year, while the company has not disclosed a specific U.S. launch timeline for Proibs.